Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 1c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Cytek Biosciences Reports Third Quarter 2025 Financial Results
November 5, 2025 4:06 PM ESTFREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (Cytek Biosciences or Cytek) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025.
Recent Highlights
Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 2025Double-digit total revenue growth year-over-year in all regions, except EMEAWorldwide revenue from biotechnology, pharmaceutical and clinical research organization (CRO) customers grew 14%... More
